Researchers at Dana-Farber Cancer Institute, Oregon Health & Science University, and University of California, San Francisco have each received a $400,000 two-year grant from the AACR-MPM Oncology Charitable Foundation Transformative Cancer Research Grants Program for cancer research.
The Association of Community Cancer Centers received a Platinum 2020 eHealthcare Leadership Award in the category of Best Healthcare Podcast for its podcast, Cancer Buzz. The annual eHealthcare Awards recognize cutting-edge digital communications teams and projects from healthcare organizations in the U.S..
Walter J. (Wally) Curran, Jr., has stepped down from his positions as NRG Oncology presiding group chair and as one of the three principal investigators of the NRG Oncology.
On Jan. 20, as required, Ned Sharpless submitted his resignation letter to the outgoing administration. Other Trump appointees did the same.
FDA has approved Xalkori (crizotinib) for pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma that is ALK-positive.
FDA has granted orphan drug designation to Pvsripo for the treatment of advanced melanoma (stage IIB-IV).
Illumina is working on a series of oncology partnerships that aim to expand the reach of its comprehensive genomic profiling family of products, TruSight Oncology.
Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center published a study in the New England Journal of Medicine on preventing a common complication to lifesaving blood stem cell transplantation in leukemia.
Study: Young people using e-cigarettes are three times more likely to become daily cigarette smokers
An analysis of a large nationally representative longitudinal study by University of California San Diego Herbert Wertheim School of Public Health and Human Longevity Science found that starting tobacco products, including e-cigarettes, before the age of 18 is a major risk factor for people becoming daily cigarette smokers.
Even though cancer center and health system leaders know this deep down, most also find no way better to measure the success of programs and providers than the inscrutable Relative Value Unit, or RVU.
